Raidy Kevin J.
Direktor/Vorstandsmitglied bei Escient Pharmaceuticals, Inc.
Profil
Raidy Kevin J. is the founder of Shipley Raidy Capital Partners.
He is currently a Director at Escient Pharmaceuticals, Inc., NodThera Ltd., Aro Biotherapeutics Co., Neuron23, Inc., and a Managing Partner at Blue Owl Healthcare Opportunities Advisors LLC.
He was formerly a Director & Venture Partner at Personal Genome Diagnostics, Inc., Director at Semma Therapeutics, Inc., Independent Director at Pliant Therapeutics, Inc., Director at Oncorus, Inc., Independent Director at Repare Therapeutics, Inc., Director at Orchard Therapeutics Plc, Managing Partner at Cowen & Co. LLC, Principal at Cantor Fitzgerald & Co., and Analyst at Ramius Securities LLC.
He received his undergraduate degree from The Wharton School of the University of Pennsylvania.
Aktive Positionen von Raidy Kevin J.
| Unternehmen | Position | Beginn |
|---|---|---|
Escient Pharmaceuticals, Inc.
 Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 14.09.2020 |
Aro Biotherapeutics Co.
 Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Direktor/Vorstandsmitglied | - |
Neuron23, Inc.
 Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Direktor/Vorstandsmitglied | - |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Cowen Investment Management LLC
 Cowen Investment Management LLC Investment ManagersFinance Cowen Investment Management LLC (Cowen Investment Management) is a venture capital subsidiary of Cowen, Inc. founded in 1997. The firm is headquartered in New York. | Private Equity Investor | - |
Ehemalige bekannte Positionen von Raidy Kevin J.
| Unternehmen | Position | Ende |
|---|---|---|
| REPARE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 18.06.2020 |
Cowen & Co. LLC
 Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Analyst-Equity | 01.04.2019 |
Ramius Securities LLC
 Ramius Securities LLC Investment Banks/BrokersFinance Founded in 1994, Ramius Securities LLC is a broker-dealer located in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. They are a subsidiary of Ramius Capital Group LLC. | Analyst-Equity | 31.05.2010 |
| ONCORUS, INC. | Direktor/Vorstandsmitglied | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Raidy Kevin J.
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PLIANT THERAPEUTICS, INC. | Health Technology |
| REPARE THERAPEUTICS INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| Private Unternehmen | 12 |
|---|---|
Ramius Securities LLC
Ramius Securities LLC Investment Banks/BrokersFinance Founded in 1994, Ramius Securities LLC is a broker-dealer located in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. They are a subsidiary of Ramius Capital Group LLC. | Finance |
Cowen & Co. LLC
Cowen & Co. LLC Investment Banks/BrokersFinance Cowen & Co. LLC is a SEC-registered broker/dealer headquartered in New York City. The firm was founded in 2004 and is a subsidiary of Cowen Holdings, Inc., ultimately owned by The Toronto-Dominion Bank (TSE: TD) in Canada. Cowen & Co. offers industry-focused investment banking for growth-oriented companies, domain knowledge-driven research and a sales and trading platform for institutional investors. Their institutional sales and trading business serves both equity and fixed-income clients. Sales and trading execution platform is structured around the following key verticals: (1) healthcare (2) technology, telecommunications and media (TMT) (3) REITs and financials (4) aerospace and defense (5) consumer and (6) alternative energy. | Finance |
| Shipley Raidy Capital Partners | |
Cantor Fitzgerald & Co.
 Cantor Fitzgerald & Co. Investment Banks/BrokersFinance Cantor Fitzgerald & Co. is the investment bank and brokerage subsidiary of CFS CF & Co. I Holdings LP, which is owned by Cantor Fitzgerald LP in the US. The firm was founded by Bernie Gerald Cantor and John Fitzgerald in 1945. Headquartered in New York City, Cantor Fitzgerald offers clients a global, multi-asset prime brokerage platform with a focus on the quality middle market. | Finance |
Semma Therapeutics, Inc.
 Semma Therapeutics, Inc. BiotechnologyHealth Technology Semma Therapeutics, Inc. develops transformative therapies for patients who currently depend on insulin injections. It focuses on combining proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. The company was founded by Robert A. Millman, Walter A. Blättler, Felicia Pagliuca, Jeff Imbaro and Douglas A. Melton in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Escient Pharmaceuticals, Inc.
Escient Pharmaceuticals, Inc. BiotechnologyHealth Technology Escient Pharmaceuticals, Inc. operates as a bio-technology company. It develops in-class G Protein-Coupled Receptor targeted drugs to address serious, unserved medical needs. The company was founded by Alain D. Baron, Marcus F. Boehm and Xinzhong Dong and is headquartered in San Diego, CA. | Health Technology |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Neuron23, Inc.
Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Health Technology |
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
Cowen Investment Management LLC
Cowen Investment Management LLC Investment ManagersFinance Cowen Investment Management LLC (Cowen Investment Management) is a venture capital subsidiary of Cowen, Inc. founded in 1997. The firm is headquartered in New York. | Finance |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
